Cargando…

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies

Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60% of patients receive salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of second-line treatment of advanced gastric cancer. MEDL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacovelli, Roberto, Pietrantonio, Filippo, Farcomeni, Alessio, Maggi, Claudia, Palazzo, Antonella, Ricchini, Francesca, de Braud, Filippo, Di Bartolomeo, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182573/ https://www.ncbi.nlm.nih.gov/pubmed/25268988 http://dx.doi.org/10.1371/journal.pone.0108940

Ejemplares similares

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
por: Pietrantonio, Filippo, et al.
Publicado: (2014)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
por: Fanotto, Valentina, et al.
Publicado: (2018)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
por: Martinetti, Antonia, et al.
Publicado: (2014)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Fasting-mimicking diet plus chemotherapy in breast cancer treatment
por: Vernieri, Claudio, et al.
Publicado: (2020)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
por: Davies, Jessica, et al.
Publicado: (2017)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
por: Celio, Luigi, et al.
Publicado: (2015)

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
por: Fornaro, Lorenzo, et al.
Publicado: (2015)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer
por: Zhang, Yong-jie, et al.
Publicado: (2020)

Unresectable Advanced Gastric Cancer with Skin Invasion followed by Total Gastrectomy after Second-Line Chemotherapy
por: Maki, Hidenori, et al.
Publicado: (2019)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
por: Provenzano, Leonardo, et al.
Publicado: (2023)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
por: Milione, Massimo, et al.
Publicado: (2017)

Second-line treatment in renal cell carcinoma: clinical experience and decision making
por: Guadalupi, Valentina, et al.
Publicado: (2021)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
por: Pusceddu, Sara, et al.
Publicado: (2016)

Author response to Colle et al
por: Fucà, Giovanni, et al.
Publicado: (2021)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
por: Ogawa, Kohei, et al.
Publicado: (2012)

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
por: Baek, Jin Ho, et al.
Publicado: (2005)

Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism
por: Pinelli, Silvia, et al.
Publicado: (2021)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l98ntk2bbsdpcrhstt5mv77rcr